Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 90 of 163 results for fibrosis

  1. Insertion of customised titanium implants, with soft tissue cover, for orofacial reconstruction (HTG307)

    Evidence-based recommendations on insertion of customised titanium implants, with soft tissue cover, for orofacial reconstruction. This involves inserting titanium implants to replace broken bones in the face as part of orofacial reconstruction.

  2. Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type B (HST32)

    Evidence-based recommendations on olipudase alfa (Xenpozyme) for treating acid sphingomyelinase deficiency (Niemann–Pick disease) in people with type AB or type B.

  3. Osteoporosis: assessing the risk of fragility fracture (CG146)

    This guideline covers assessing the risk of fragility fracture in people aged 18 and over with osteoporosis. It aims to provide guidance on the selection and use of risk assessment tools in the care of adults at risk of fragility fractures in all NHS settings.

  4. CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic (MIB219)

    NICE has developed a medtech innovation briefing (MIB) on CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic .

  5. Psoriasis: assessment and management (CG153)

    This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.

  6. Selective internal radiation therapy for primary hepatocellular carcinoma (HTG314)

    Evidence-based recommendations on selective internal radiation therapy (SIRT) for primary hepatocellular carcinoma. This involves infusion of microspheres loaded with yttrium-90, which aims to deliver radiation directly into the tumour, minimising the risk of radiation damage to healthy surrounding tissues.

  7. Data collection agreement

    can make Modular updates This agreement relates to treating cystic fibrosis patients with: Ivacaftor, tezacaftor and elexacaftor...

  8. Telbivudine for the treatment of chronic hepatitis B (TA154)

    Evidence-based recommendations on telbivudine (Sebivo) for treating chronic hepatitis B in adults.

  9. Percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain (HTG399)

    Evidence-based recommendations on percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain. This involves relieving low back pain by delivering heat energy to the damaged disc.

  10. Cardiac MRI versus other imaging techniques for diagnosing heart failure:- What is the optimal imaging technique for the diagnosis of heart failure?

    structure and metabolism, including the presence of inflammation, scarring, fibrosis and infiltration. Cardiac MRI is an expensive form...

  11. Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)

    Evidence-based recommendations on using Intrabeam radiotherapy during breast-conserving surgery in adults.

  12. Sofosbuvir–velpatasvir for treating chronic hepatitis C (TA430)

    Evidence-based recommendations on sofosbuvir–velpatasvir (Epclusa) for treating chronic hepatitis C in adults.

  13. Assessing the risk of cirrhosis:- Development of a risk tool to identify people at risk of cirrhosis.

    identify people who are at high risk of having, or developing, advanced liver fibrosis or cirrhosis.One approach would be to identify a...

  14. Non-invasive tests for diagnosing NAFLD in adults:- Which non-invasive tests are most accurate and cost-effective in identifying non-alcoholic fatty liver disease (NAFLD) in adults with risk factors, type 2 diabetes and metabolic syndrome?

    2 diabetes mellitus or metabolic syndrome. Untreated it can progress to fibrosis, cirrhosis and hepatocellular cancer. In most patients...

  15. Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)

    Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (also known as Viekirax) with or without dasabuvir (also known as Exviera) for adults with some types (called genotypes) of chronic hepatitis C.